---
title: "Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298915465.md"
description: "Akebia Therapeutics has dosed the first patient in an open-label Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseases. The study aims to assess whether the drug can reduce kidney inflammation and protein leakage while maintaining immune defenses, with up to 30 patients planned. Initial results are not yet available, with first data expected in 2027. This milestone positions the program for a go/no-go decision on broader development."
datetime: "2026-09-14T12:07:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298915465.md)
  - [en](https://longbridge.com/en/news/298915465.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298915465.md)
generator: "portal-rs"
---

# Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases

-   Akebia Therapeutics dosed the first patient in an open-label Phase 2 basket trial of ebribafusp for rare kidney diseases. \* Initial results have not been presented; first data are expected in 2027. \* The study aims to show whether the drug can reduce kidney inflammation and protein leakage while maintaining broader immune defenses. \* Up to 30 patients are planned, positioning the program for a clearer go/no-go decision on broader development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED9826135) on September 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AKBA.US](https://longbridge.com/en/quote/AKBA.US.md)

## Related News & Research

- [Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital](https://longbridge.com/en/news/298343412.md)
- [Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead](https://longbridge.com/en/news/298914581.md)
- [Why Vera Therapeutics stock is jumping on new kidney drug trial results](https://longbridge.com/en/news/299076533.md)
- [VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead](https://longbridge.com/en/news/298920359.md)
- [EVMN: Innovative therapies for inflammation, migraine, and autoimmunity advance toward late-stage trials](https://longbridge.com/en/news/299090006.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**